![\"\"](\"http:\/\/wnyretina.files.wordpress.com\/2012\/05\/eyedrops11.jpg\" "\\"eyedrops1\\"")
<\/a><\/p>\nActive Studies:<\/strong><\/p>\n <\/p>\n 1.\u00a0 Sponsor:<\/strong><\/p>\n Diabetic Retinopathy Clinical Research Network (DRCR)<\/a><\/p>\n Principal Investigator:<\/strong><\/p>\n Dr. Paul Lee<\/p>\n Clinical Trial Title:<\/strong><\/p>\n Protocol N<\/strong><\/p>\n An Evaluation of Intravitreal Ranibizumab (Lucentis) for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy<\/p>\n Synopsis:<\/strong><\/p>\n To evaluate intravitreal ranibizumab (Lucentis) as treatment for vitreous hemorrhage from proliferative diabetic retinopathy in order to avoid vitrectomy.<\/p>\n NOT CURRENTLY ENROLLING<\/strong><\/p>\n <\/p>\n 2. Sponsor:<\/strong><\/p>\n Regeneron Pharmaceuticals Inc.<\/a><\/p>\n Principal Investigator:<\/strong><\/p>\n Dr. Paul Lee<\/p>\n <\/p>\n Clinical Trial Title:<\/strong><\/p>\n VGFT-OD-1009<\/strong><\/p>\n A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema<\/strong><\/p>\n Synopsis:<\/strong><\/p>\n To assess the efficacy and safety of intravitreal (IVT) administration of vascular endothelial growth factor (VEGF) Trap-Eye compared to laser treatment in improving best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME).<\/p>\n NOT CURRENTLY ENROLLING<\/strong><\/p>\n <\/p>\n 3.<\/strong> Sponsor: <\/strong><\/p>\n Regeneron Pharmaceuticals Inc.<\/a><\/p>\n Principal Investigator:<\/strong><\/p>\n Dr. Mehdi Khan<\/p>\n Clinical Trial Title:<\/strong><\/p>\n VGFTe-RVO-1027<\/strong><\/p>\n A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion<\/p>\n Synopsis:<\/strong><\/p>\n To assess the efficacy and safety of intravitreal (IVT) administration of vascular endothelial growth factor (VEGF) Trap-Eye in improving best corrected visual acuity (BCVA), compared to laser treatment, in patients with macular edema secondary to branch retinal vein occlusion (BRVO).<\/p>\n 4.<\/strong> Sponsor:<\/strong><\/p>\n Santen Inc.<\/a><\/p>\n Principal Investigator:<\/strong><\/p>\n Dr. Ramakrishna Ratnakaram<\/p>\n <\/p>\n Clinical Trial Title:<\/strong><\/p>\n Santen 32-007<\/strong><\/p>\n A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye<\/p>\n Synopsis:<\/strong><\/p>\n To evaluate the safety and efficacy of intravitreal injections of DE-109 (44ug, 440ug, 880ug) for the treatment of active, non-infectious uveitis of the posterior segment of the eye.<\/p>\n","protected":false},"excerpt":{"rendered":" Retina Consultants of Western New York strives to educate and treat our patients with precision, confidence and dedication. With these three ideals in mind we actively participate in clinical studies that we feel further the care of our patients. The … Continue reading \n
<\/a><\/p>\n<\/a><\/p>\n<\/a><\/p>\n<\/a><\/p>\n